GAD2 and type 1 diabetes mellitus: Besides the expected differences in several recipient factors such as age, BMI, ethnicity and duration of diabetes, T2D patients has lower positivity for GAD65 autoantibody and was more frequently treated with ATG and ALEM induction and early steroid withdrawal compared to T1D patients (p < .001).